Join our daily newsletter At The Bell to receive exclusive market insights
- Australia’s Therapeutic Goods Administration (TGA) registers a saliva-based protocol for testing samples using Genetic Signatures’ (GSS) 3base EasyScreen detection kit
- A recent study by scientists in South Africa demonstrated that saliva swabs could be more effective than nasal swabs in detecting the Omicron variant
- This is due to saliva having a higher ribonucleic acid (RNA) load than nasal samples
- Genetic Signatures ends the day 5.41 per cent in the green with shares trading at $1.76 each
Australia’s Therapeutic Goods Administration (TGA) has registered a saliva-based protocol for testing samples using Genetic Signatures’ (GSS) 3base EasyScreen detection kit.
A recent study by scientists in South Africa demonstrated that saliva swabs could be more effective than nasal swabs in detecting the Omicron variant. This is due to saliva having a higher ribonucleic acid (RNA) load than nasal samples.
The Delta variant is most effectively detected via nasal swabs.
Genetic Signatures’ EasyScreen test is based on real-time PCR tests and enables the detection of SARS-CoV-2, the virus that causes COVID-19, via two gene targets.
Last month, the company announced its detection kit could detect all known variants of COVID-19, including Omicron.
“Our team is driven to provide our customers with the highest quality tests and are constantly looking ay ways to improve our products so they remain effective in detecting pathogens,” CEO Dr John Melki said.
“We are pleased that this study and subsequent registration has been completed so quickly.
“With Omicron becoming the dominant strain of the SARS-CoV-2 virus, it is likely that this new methodology will be needed to identify all cases of this new variant.”
Genetic Signatures has ended the day 5.41 per cent in the green with shares trading at $1.76 each for a $238.2 million market cap.
